Phathom Pharmaceuticals (NASDAQ:PHAT – Get Rating) had its price objective cut by Guggenheim from $42.00 to $30.00 in a research note issued to investors on Friday morning, MarketBeat reports. They currently have a buy rating on the stock.
Several other research firms also recently weighed in on PHAT. The Goldman Sachs Group decreased their price target on shares of Phathom Pharmaceuticals from $15.00 to $9.00 and set a neutral rating for the company in a research note on Wednesday, August 3rd. Jefferies Financial Group assumed coverage on shares of Phathom Pharmaceuticals in a research note on Thursday, October 20th. They set a buy rating and a $16.00 price target for the company. Needham & Company LLC decreased their price target on shares of Phathom Pharmaceuticals from $44.00 to $38.00 and set a buy rating for the company in a research note on Wednesday, August 3rd. Finally, BMO Capital Markets decreased their price target on shares of Phathom Pharmaceuticals from $54.00 to $45.00 in a research note on Wednesday, August 3rd.
Phathom Pharmaceuticals Stock Performance
Phathom Pharmaceuticals stock opened at $10.59 on Friday. The company has a 50 day moving average price of $10.06 and a 200-day moving average price of $9.34. The company has a debt-to-equity ratio of 2.39, a quick ratio of 9.93 and a current ratio of 9.93. Phathom Pharmaceuticals has a fifty-two week low of $6.09 and a fifty-two week high of $22.58. The company has a market capitalization of $440.77 million, a PE ratio of -2.27 and a beta of 0.39.
Hedge Funds Weigh In On Phathom Pharmaceuticals
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
- Get a free copy of the StockNews.com research report on Phathom Pharmaceuticals (PHAT)
- Alphabet Stock Offers a Rare Buying Opportunity
- Walt Disney Stock is Set to Reset Expectations
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- S&P 500 Component DexCom Set For Further Price, Earnings Growth
- MarketBeat: Week in Review 11/7 – 11/11
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.